 | Imatinib | IC50 | 234.0 [1] |
| Imatinib | Ki | 13.0 [1], 37.0 [2], 7000.0 [3] |
 | Ponatinib | IC50 | 1.08 [1] |
 | Dasatinib | IC50 | 1.0 [1] |
 | Nilotinib | IC50 | 28.0 [1] |
 | Staurosporine | IC50 | 105.9 [1] |
 | Bosutinib | IC50 | 1.1 [1] |
 | CID 51038269 | IC50 | 0.34 [1] |
 | CID 71605047 | IC50 | 0.3 [1] |
 | 4-Methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-([1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]benzamide | IC50 | 3.2 [1] |
 | N-[4-[(4-Methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 0.46 [1] |
 | 4-Ethyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 1.92 [1] |
 | 4-Cyclopropyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 4.44 [1] |
 | 4-Chloro-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 0.77 [1] |
 | 4-Methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(3-methyl-2H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 0.63 [1] |
 | 3-[2-(3-Cyclopropyl-2H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide | IC50 | 0.93 [1] |
 | 4-Methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(3-phenyl-2H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 3.47 [1] |
 | 3-[2-(3-Methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide | IC50 | 5.15 [1] |
 | 3-[2-(1H-Indazol-5-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide | IC50 | 29.1 [1] |
 | 4-Methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1-methylpyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide | IC50 | 1.08 [1] |
 | 1-[5-(2-Imidazo[1,2-a]pyrazin-5-ylethynyl)-1-methylpyrazol-3-yl]-3-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]urea | IC50 | 1.6 [1] |
 | 1-[5-(2-Imidazo[1,2-a]pyrazin-3-ylethynyl)-1-methylpyrazol-3-yl]-3-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]urea | IC50 | 0.5 [1] |
 | 1-[5-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-1-methylpyrazol-3-yl]-3-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]urea | IC50 | 0.4 [1] |
 | CID 11478363 | IC50 | 61.0 [1] |
 | Bcr-abl Inhibitor II | Ki | 120.0 [1] |
 | 1-(2-Chloro-2-phenylethyl)-N-[(3-fluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 40.0 [1], 16700.0 [2] |
 | 3-[(E)-2-[6-(Cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]benzamide | IC50 | 25.0 [1], 400.0 [2], 478.0 [3], 25000.0 [4] |
 | 1-[2-Chloro-2-(4-fluorophenyl)ethyl]-N-(3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 700.0 [1], 732.0 [2], 750.0 [3], 2430.0 [4], 3000.0 [5] |
 | N-[3-(7-Anilino-1-methyl-2-oxo-4H-pyrimido[4,5-d]pyrimidin-3-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide | IC50 | 5.0 [1], 130.0 [2], 135.0 [3], 206.0 [4] |
 | Sunitinib | IC50 | 410.0 [1], 504.0 [2], 1613.0 [3], 50000.0 [4] |
 | Axitinib | IC50 | 0.42 [1], 0.55 [2], 2.6 [3], 7.78 [4] |
 | N-Benzyl-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 260.0 [1], 300.0 [2] |
 | 7-(2,6-Dichlorophenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine | Ki | 19.4 [1], 20.0 [2], 10300.0 [3] |
 | N-Benzyl-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 370.0 [1], 400.0 [2] |
 | N-[3-(7-Amino-1-methyl-2-oxo-4H-pyrimido[4,5-d]pyrimidin-3-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide | IC50 | 5.0 [1], 1567.0 [2] |
 | 7-(2,6-Dimethylphenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine | IC50 | 20.0 [1], 5990.0 [2] |
| 7-(2,6-Dimethylphenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine | Ki | 11.0 [1], 4240.0 [2] |
 | 1-[2-Chloro-2-(4-chlorophenyl)ethyl]-N-(4-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 80.0 [1], 160.0 [2] |
 | 6-Bromo-3-[(3E)-3-[2-[4-(2-methoxyethyl)piperazin-1-yl]ethoxyimino]indol-2-yl]-1H-indol-2-ol | IC50 | 468.0 [1], 3440.0 [2], 10000.0 [3] |
 | 3-(2-Imidazo[1,2-a]pyridin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide | IC50 | 1.4 [1], 1.6 [2], 9.0 [3], 56.0 [4] |
 | 3-[(E)-2-[6-(Cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide | IC50 | 20.0 [1], 14142.0 [2], 14412.0 [3], 20000.0 [4] |
 | 3-[(E)-2-[6-(Cyclopropylamino)purin-9-yl]ethenyl]-N-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide | IC50 | 13.0 [1], 542.0 [2], 13000.0 [3] |
 | 3-(4-Methylimidazol-1-yl)-N-[4-methyl-3-[1-methyl-7-(methylamino)-2-oxo-4H-pyrimido[4,5-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethyl)benzamide | IC50 | 5.0 [1], 720.0 [2] |
 | CID 46864270 | IC50 | 0.2 [1], 0.4 [2], 17.2 [3], 60.2 [4] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.13 [1], 0.5 [2], 1.0 [3], 213.0 [4] |
 | Methyl 5-[[2-methyl-5-[[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)benzoyl]amino]phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate | IC50 | 6.0 [1], 46.0 [2], 51.0 [3], 73.0 [4] |
 | 6-[(3R)-3-Hydroxypyrrolidin-1-yl]-5-pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]pyridine-3-carboxamide | IC50 | 1.2 [1], 3.0 [2], 4.0 [3], 88.0 [4] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.13 [1], 0.3 [2], 3.0 [3], 13.0 [4] |
 | 6-[(3R)-3-Hydroxypyrrolidin-1-yl]-5-pyrimidin-5-yl-N-[4-(trifluoromethylsulfanyl)phenyl]pyridine-3-carboxamide | IC50 | 0.2 [1], 0.4 [2], 5.0 [3], 19.0 [4] |
 | Crizotinib | IC50 | 24.0 [1], 1000.0 [2], 1159.0 [3] |
 | Seliciclib | IC50 | 10000.0 [1], 100000.0 [2] |
 | Saracatinib | IC50 | 30.0 [1] |
 | Danusertib | IC50 | 5.0 [1], 7.94 [2], 25.0 [3] |
 | 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea | IC50 | 4.0 [1], 10.0 [2] |
 | 3-(6-((4-(Trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)benzamide | IC50 | 9.0 [1], 2800.0 [2], 10000.0 [3] |
 | 1-(2-Chloro-2-phenylethyl)-6-(methylthio)-N-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 7030.0 [1], 7300.0 [2] |
 | 1-Cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | IC50 | 2.0 [1], 18.0 [2] |
 | Gnf-5 | IC50 | 17.0 [1], 2000.0 [2], 10000.0 [3] |
 | 1-(2-Chloro-2-phenylethyl)-N-(3-chlorophenyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 600.0 [1] |
 | N-(3-Chlorophenyl)-1-(2-chloro-2-phenylethyl)-6-(2-morpholin-4-ylethylsulfanyl)pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 120.0 [1], 180.0 [2] |
 | 1-(2-Chloro-2-phenylethyl)-6-(2-morpholin-4-ylethylsulfanyl)-N-phenylpyrazolo[3,4-d]pyrimidin-4-amine | Ki | 150.0 [1], 220.0 [2] |
 | N-(3-Bromophenyl)-6-methylsulfanyl-1-(2-phenylpropyl)pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 1070.0 [1] |
 | N-[3-[2-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)ethynyl]phenyl]-3-(trifluoromethyl)benzamide | IC50 | 0.6 [1], 0.8 [2] |
 | 1-[2-Chloro-2-(4-fluorophenyl)ethyl]-N-[(3-fluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine | Ki | 100.0 [1], 23600.0 [2] |
 | 1-(1-Methylethyl)-3-Quinolin-6-Yl-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine | IC50 | 42.0 [1], 140.0 [2] |
 | 1-Cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | IC50 | 170.0 [1], 340.0 [2] |
 | 1-[2-(4-Bromophenyl)-2-chloroethyl]-N-phenylpyrazolo[3,4-d]pyrimidin-4-amine | Ki | 90.0 [1], 610.0 [2] |
 | 6-[(3S)-3-Hydroxypyrrolidin-1-yl]-5-pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]pyridine-3-carboxamide | IC50 | 2.3 [1], 4.8 [2], 9.0 [3] |
 | 3-Pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]benzamide | IC50 | 3.4 [1], 5.6 [2], 18.0 [3] |
 | 6-[(3R)-3-Hydroxy-3-methylpyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]pyridine-3-carboxamide | IC50 | 1.6 [1], 2.5 [2], 2.8 [3] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-5-(5-fluoropyridin-3-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide | IC50 | 0.13 [1], 4.0 [2], 12.0 [3] |
 | 5-(5-Fluoropyridin-3-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]-N-[4-(trifluoromethylsulfinyl)phenyl]pyridine-3-carboxamide | IC50 | 11.0 [1], 15.0 [2], 580.0 [3] |
 | 6-[(3R)-3-Hydroxypyrrolidin-1-yl]-N-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.6 [1], 3.0 [2], 130.0 [3] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-5-(5-cyanopyridin-3-yl)-6-[2-hydroxyethyl(methyl)amino]pyridine-3-carboxamide | IC50 | 0.2 [1], 4.0 [2], 38.0 [3] |
 | 5-(5-Fluoropyridin-3-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]-N-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]pyridine-3-carboxamide | IC50 | 7.0 [1], 11.0 [2], 442.0 [3] |
 | N-[4-[Chloro(difluoro)methyl]sulfanylphenyl]-5-(5-fluoropyridin-3-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide | IC50 | 0.6 [1], 3.0 [2], 10.0 [3] |
 | N-[4-(2-Chloro-1,1,2,2-tetrafluoroethyl)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.5 [1], 1.0 [2], 24.0 [3] |
 | 5-(5-Fluoropyridin-3-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]pyridine-3-carboxamide | IC50 | 0.2 [1], 4.0 [2], 24.0 [3] |
 | N-[3-Fluoro-4-(trifluoromethoxy)phenyl]-6-[(3S)-3-(hydroxymethyl)pyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 1.9 [1], 4.0 [2], 273.0 [3] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-5-(5-cyanopyridin-3-yl)-6-[(3R,4S)-3,4-dihydroxypyrrolidin-1-yl]pyridine-3-carboxamide | IC50 | 0.4 [1], 0.5 [2], 93.0 [3] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3R,4S)-3-hydroxy-4-(hydroxymethyl)piperidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.6 [1], 3.0 [2], 38.0 [3] |
 | 6-(3-Hydroxy-3-methylazetidin-1-yl)-5-(2-methylpyrimidin-5-yl)-N-[4-(trifluoromethoxy)phenyl]pyridine-3-carboxamide | IC50 | 5.4 [1], 8.0 [2], 513.0 [3] |
 | 6-[(3R)-3-(Aminomethyl)pyrrolidin-1-yl]-5-pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]pyridine-3-carboxamide | IC50 | 0.6 [1], 3.0 [2], 800.0 [3] |
 | N-[4-(1,1-Difluoroethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 1.2 [1], 7.9 [2], 554.0 [3] |
 | 4-[(3S,4S)-3-Amino-4-hydroxypyrrolidin-1-yl]-N-[4-[chloro(difluoro)methoxy]phenyl]-3-(5-fluoropyridin-3-yl)benzamide | IC50 | 0.6 [1], 1.0 [2], 165.0 [3] |
 | N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3S,4R)-3,4-dihydroxypyrrolidin-1-yl]-5-pyrimidin-5-ylpyridine-3-carboxamide | IC50 | 0.7 [1], 1.0 [2], 130.0 [3] |
 | Genistein | IC50 | 10000.0 [1] |
 | Sorafenib | IC50 | 80.0 [1], 120.0 [2] |
 | Mebendazole | IC50 | 5000.0 [1] |
| Mebendazole | Ki | 4600.0 [1] |
 | Ibrutinib | IC50 | 86.1 [1] |
 | Vandetanib | IC50 | 86.0 [1], 151.0 [2] |
 | Semaxanib | IC50 | 10000.0 [1], 11000.0 [2] |
 | Tozasertib | Ki | 30.0 [1], 42.0 [2] |
 | Dovitinib | IC50 | 228.0 [1], 450.0 [2] |
 | 2-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol | IC50 | 410.0 [1], 3600.0 [2] |
 | (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine | IC50 | 81.0 [1], 295.0 [2] |
 | PDGF Receptor Tyrosine Kinase Inhibitor IV | IC50 | 22.0 [1] |
 | 1-Tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | IC50 | 120.0 [1], 3400.0 [2] |
 | 3-(1H-Indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridine | IC50 | 3.0 [1], 6.8 [2] |
Calculator
